Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mutagrip is a brand name for a trivalent inactivated influenza vaccine, produced by Sanofi Pasteur. It is formulated to provide active immunization against influenza caused by the specific strains of influenza virus contained in the vaccine, which are selected annually based on World Health Organization (WHO) recommendations. Each standard dose contains 15 micrograms of haemagglutinin antigen per strain for two A strains (H1N1 and H3N2) and one B strain. The vaccine is administered intramuscularly and is indicated for adults and children 6 months of age and older. The mechanism of action involves stimulating an immune response that leads to the production of antibodies against the hemagglutinin surface glycoprotein of the included influenza virus strains, thereby providing protection against infection[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mutagrip.